First in class small molecule modulators of DNA repair mechanisms
KuDos’ platform, developed by Professor Steve Jackson, discovered oncology therapies based upon the inhibition of DNA repair. Lynparza™ (Olaparib), was the first approved PARP inhibitor for women with BRCA-mutated advanced ovarian cancer who have been treated with three or more lines of chemotherapy.
CEO Barrie Ward
Advent invested in Series A in 1999. KuDos was acquired by Astra Zeneca in 2005.
Cancer drug developed by former Advent Venture Partners portfolio company, KuDOS Pharma (sold to AstraZeneca in 2006) shows promise
Press Release. Researchers say a new type of cancer treatment has produced highly promising results in preliminary drug trials. Olaparib was given to 19 patients with inherited forms…Read More